Professor Dror Meirow is the head of the Clinical Center for Fertility Preservation and the Fertility Preservation Research Laboratory at Sheba Medical Center, Tel-Hashomer, Israel. He is also a Professor at the Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Prof. Meirow received his M.D. from the Hebrew University of Jerusalem, Israel. He then specialized and practiced as a senior physician at the Department of Obstetrics and Gynecology at Hadassah University Hospital. He conducted his basic research training at the Center for Reproduction Growth and Development, at the University of Leeds, UK, under the guidance of Prof. Roger Gosden. Since 2001, he has headed the Clinical Center for Fertility Preservation and the Fertility Preservation Research Laboratory at Sheba Medical Center. He has guided and supervised dozens of doctors, embryologists and students from different countries in their clinical and basic studies in the field of fertility preservation.
In his clinical practice Professor Meirow is specializing in all aspects of reproductive medicine, including infertility treatments, assisted reproductive technologies (ART), IVF, egg donation and surrogacy, as well as ovarian tissue cryopreservation and transplantation.
Professor Meirow's basic and clinical research is focused on the effects of chemotherapy on reproduction, and modalities for fertility preservation in cancer patients, including ovarian tissue harvesting, egg and embryo freezing, and medications that can prevent chemotherapy-induced ovarian damage. He has written more than a hundred original articles, reviews, monographs, book chapters and position papers on these subjects.
Prof. Meirow reported the first case of pregnancy (through IVF) and delivery of a healthy baby to result from transplantation of cryopreserved ovarian tissue to a cancer survivor, who had become sterile following her cancer treatment (published in the New England Journal of Medicine). Recently, a team of researchers from Prof. Meirow's laboratory published a pioneer study in Science Journal providing a new understanding of the mechanisms involved in chemotherapy-induced ovarian damage, and are testing a novel fertility-protecting agent. For their achievements, the team of researchers led by Prof. Meirow received dozens of national and international grants during the last years.
Prof. Meirow was among the founders of:
ISFP (International Society For Fertility Preservation) – Vice President
FPSIG (American Fertility Preservation Special Interest Group)
European Fertility Preservation Task Force
Israel Cancer Association – Head of fertility forum and committee